How are we advocating for Kidney Cancer? Find out HERE
In the News
What’s the latest in the news regarding Kidney Cancer?
Smart Patients is an online community where patients and their families learn from each other. Patients can be extraordinarily knowledgeable about their disease. Get information and support from patients who have expertise to share with you.
NBC Today Anchor Marc Fein: I had the honor of talking to DMN Dallas City Columnist Robert Wilonsky today about his battle with cancer. He was told he wouldn’t see his son’s next birthday. He did, and his story is remarkable.
Researchers at the National Institutes of Health (NIH) in Bethesda, Maryland, are enrolling patients with kidney cancer (renal cell carcinoma) into a gene therapy study– a new type of precision medicine that genetically reprograms your immune cells to specifically recognize and kill tumor cells.
Daniel George, MD; Toni Choueiri, MD; Walter Stadler, MD; and Richard W. Joseph, MD, discuss data from the CABOSUN trial and the expanded FDA approval for cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma.
The first NHS cancer patient to benefit from a breakthrough procedure that primes the body’s immune system to ‘seek and destroy’ tumour cells has stunned doctors with his recovery after being given just weeks to live.
Adi Diab, MD, discusses the synergistic mechanisms of NKTR-214 and nivolumab and the promising results of the phase I/II PIVOT-02 trial evaluating the use of NKTR-214 combined with nivolumab in multiple solid tumor types.
Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the role of PD-L1 in metastatic renal cell carcinoma (RCC).
Pembrolizumab monotherapy in the first-line setting induced a response among nearly 40% of patients with clear cell renal cell carcinoma across all IMDC risk groups, according to interim results from cohort A of the KEYNOTE-427 trial presented at the ASCO Annual Meeting.
Charles G. Drake, MD, PhD, professor of medical oncology at New York Presbyterian/Columbia University Medical Center, discusses his thoughts on whether sunitinib would be more successful as a treatment for patients with renal cell carcinoma if used in the neoadjuvant setting. He debates whether immunotherapies or neoadjuvant therapies would be more useful.
72-year-old Larry Carlson was diagnosed with stage IV CCRCC in November of 2014. He came to the UT Southwestern Kidney Cancer Program shortly after. Larry shares his journey through diagnosis, surgery, and immunotherapy.
Congressionally-directed Medical Research Program. It took over a decade of hard work from kidney cancer advocates to obtain kidney cancer-specific research funding included in the federal budget. Nevertheless, in March of 2017 Congress approved and the president signed the Consolidation Appropriations Act.